A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis - The membrane study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Dorsch, Oliver ^a   Krieter, Detlef H ^b   Lemke, Horst Dieter ^c   Fischer, Stefan ^d   Melzer, Nima ^e   Sieder, Christian ^e   Bramlage, Peter ^f   Harenberg, Job ^g  

^a KfH Nierenzentrum ^*  (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c eXcorLab GmbH   (Germany)

^d Dialyse Centrum Darmstadt   (Germany)

^e NOVARTIS PHARMA GMBH   (Germany)

^f Institute für Pharmakologie und Präventive Medizin   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; MONOEMBOLEX;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTINUOUS INFUSION; DIALYSIS MEMBRANE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPISTAXIS; FEASIBILITY STUDY; FEMALE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FLUTTER; HEMATOMA; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; INJURY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; ORAL BLEEDING; PATIENT SATISFACTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; SINGLE DRUG DOSE; THORAX PAIN; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS;

EID: 84862753214     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-50     Document Type: Article

References (32)

1. Effect of anticoagulation on blood membrane interactions during hemodialysis. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W, Kidney Int 1999 56 4 1578 1583 10.1046/j.1523-1755.1999. 00671.x 10504511 (Pubitemid 29451266)
2. Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. Davenport A, Nephrology (Carlton) 2009 14 5 455 461 10.1111/j.1440-1797.2009.01135.x
3. What are the anticoagulation options for intermittent hemodialysis? Davenport A, Nat Rev Nephrol 2011 Jul 5 7 9 499 508
4. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Wiemer J, Winkler K, Baumstark M, Marz W, Scherberich JE, Nephrol Dial Transplant 2002 17 12 2231 2238 10.1093/ndt/17.12.2231 12454238 (Pubitemid 35446683)
5. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Elisaf MS, Germanos NP, Bairaktari HT, Pappas MB, Koulouridis EI, Siamopoulos KC, Am J Nephrol 1997 17 2 153 157 10.1159/000169090 9096446 (Pubitemid 27141906)
6. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Lim W, Dentali F, Eikelboom JW, Crowther MA, Ann Intern Med 2006 144 9 673 684 16670137 (Pubitemid 46780653)
7. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients. Schrader J, Stibbe W, Kandt M, Warneke G, Armstrong V, Muller HJ, Scheler F, ASAIO Trans 1990 36 1 28 32 2155017 (Pubitemid 20110729)
8. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH, Thromb Haemost 2005 94 6 1265 1269 16411404 (Pubitemid 41819625)
9. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Shantsila E, Lip GY, Chong BH, Chest 2009 135 6 1651 1664 10.1378/chest.08-2830 19497901
10. Heparin-induced osteoporosis. Nelson-Piercy C, Scand J Rheumatol Suppl 1998 107 68 71 9759137 (Pubitemid 28432949)
11. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Hottelart C, Achard JM, Moriniere P, Zoghbi F, Dieval J, Fournier A, Artif Organs 1998 22 7 614 617 10.1046/j.1525-1594.1998.06204.x 9684701 (Pubitemid 28324038)
12. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Melzer N, Bramlage P, Riess H, Thromb Haemost 2011 105 6 981 988 10.1160/TH10-09-0614 21505722
13. Antagonisation of low molecular weight heparin by protamine hydrochloride. Harenberg J, Giese C, Knödler A, Zimmermann R, Schettler G, Herz/Kreislauf 1986 18 578 581 (Pubitemid 17214431)
14. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Hoffmann U, Harenberg J, Bauer K, Huhle G, Tolle AR, Feuring M, Christ M, Blood Coagul Fibrinolysis 2002 13 4 289 296 10.1097/00001721-200206000-00003 12032393 (Pubitemid 35001868)
15. Certoparin for thrombosis prophylaxis in geriatric patients: accumulation in connection with age-associated reduction of renal function. Rahn A, Euro J Ger 2008 10 28 32
16. Niedermolekulare Heparine zur Prophylaxe venöser Thromboembolien bei Patienten mit Niereninsuffizienz. Bauersachs R, Bramlage P, vasomed 2011 23 118 122
17. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. Lim W, Cook DJ, Crowther MA, J Am Soc Nephrol 2004 15 12 3192 3206 10.1097/01.ASN.0000145014.80714.35 15579523 (Pubitemid 39578852)
18. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. Harenberg J, Kramer R, Giese C, Marx S, Weiss C, Wehling M, J Thromb Thrombolysis 2011 32 3 267 271 10.1007/s11239-011-0622-5 21811937
19. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F, Kidney Int 1988 33 4 890 896 10.1038/ki.1988.81 2838681
20. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, Dussol B, Brunet P, Nephrol Dial Transplant 2003 18 11 2348 2353 10.1093/ndt/gfg396 14551364 (Pubitemid 37336823)
21. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Lord H, Jean N, Dumont M, Kassis J, Leblanc M, Am J Nephrol 2002 22 1 58 66 10.1159/000046675 11919404 (Pubitemid 34264187)
22. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL, Nephrol Dial Transplant 1995 10 2 217 222 7753456
23. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Stefoni S, Cianciolo G, Donati G, Coli L, La Manna G, Raimondi C, Dalmastri V, Orlandi V, D'Addio F, Nephron 2002 92 3 589 600 10.1159/000064086 12372942
24. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Moia M, Graziani G, Tenconi PM, Martinelli I, Ponticelli C, Ann Ital Med Int 1997 12 2 67 71 9284597 (Pubitemid 27313235)
25. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR, Nephrol Dial Transplant 1990 5 2 135 140 10.1093/ndt/5.2.135 2162506 (Pubitemid 20154872)
26. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. Klingel R, Schwarting A, Lotz J, Eckert M, Hohmann V, Hafner G, Kidney Blood Press Res 2004 27 4 211 217 10.1159/000079866 15273423 (Pubitemid 39279325)
27. Anticoagulation during dialysis and/or continuous therapy. LMWH or heparin vs. citrate. Davenport A, Eu J Hosp Pharm 2007 13 64 66
28. Prothrombotic changes in platelet, endothelial and coagulation function following hemodialysis. Milburn JA, Cassar K, Ford I, Fluck N, Brittenden J, Int J Artif Organs 2011 34 3 280 287 10.5301/IJAO.2011.6469 21445833
29. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Brosstad F, Nephrol Dial Transplant 2001 16 5 987 993 10.1093/ndt/16.5.987 11328905 (Pubitemid 32440371)
30. Anticoagulation options for intermittent haemodialysis. Davenport A, Minerva Urol Nefrol 2006 58 2 171 180 16767070 (Pubitemid 43962393)
31. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Saltissi D, Morgan C, Westhuyzen J, Healy H, Nephrol Dial Transplant 1999 14 11 2698 2703 10.1093/ndt/14.11.2698 10534515 (Pubitemid 32208389)
32. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Polkinghorne KR, McMahon LP, Becker GJ, Am J Kidney Dis 2002 40 5 990 995 10.1053/ajkd.2002.36331 12407644 (Pubitemid 35265479)